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Colorectal cancer (CRC) is often diagnosed at a late stage with concomitant poor prognosis. Early detection greatly improves
prognosis; however, the invasive, unpleasant and inconvenient nature of current diagnostic procedures limits their applicability. No
serum-based test is currently of sufficient sensitivity or specificity for widespread use. In the best currently available blood test,
carcinoembryonic antigen exhibits low sensitivity and specificity particularly in the setting of early disease. Hence, there is great need
for new biomarkers for early detection of CRC. We have used surface-enhanced laser desorbtion/ionisation (SELDI) to investigate
the serum proteome of 62 CRC patients and 31 noncancer subjects. We have identified proteins (complement C3a des-arg,
a1-antitrypsin and transferrin) with diagnostic potential. Artificial neural networks trained using only the intensities of the SELDI peaks
corresponding to identified proteins were able to classify the patients used in this study with 95% sensitivity and 91% specificity.
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Colorectal cancer (CRC) is a major cause of worldwide morbidity
and mortality and is the second most common cause of cancer
death in Europe and the United States causing more than
50000 deaths in the US and 16000 in the UK each year (Greenlee
et al, 2001; CRUK, 2004). CRC follows a gradual progression
from benign polyps through early cancers to late and metastatic
cancers (Jackman and Mayo, 1951; Tierney et al, 1990). Screening
programmes for early diagnoses have resulted in a reduction
in mortality (Newcomb et al, 1992; Selby et al, 1992; Muller and
Sonnenberg, 1995) because survival decreases with increasing
stage. Endoscopic examination of the colon remains the gold
standard for diagnosis; however, this is invasive, unpleasant and
carries associated risk of morbidity and mortality. Identification of
high-risk patients using a less invasive test would decrease the
number of such procedures required. Carcinoembryonic antigen
(CEA) is of proven benefit in prognosis and follow-up, but has
limited sensitivity (30–40%) for early CRC (Fletcher, 1986),
whereas serial faecal occult blood testing is proven to reduce
CRC mortality but suffers from significant false-negative and false-
positive rates (Hardcastle et al, 1989; Mandel et al, 1993; Kronberg
et al, 1996). Stool DNA analysis for multiple targets has shown
sensitivity of 71–91% in preliminary studies and larger studies are
underway (Ahlquist et al, 2000; Dong et al, 2001); however, a
serum-based assay with equivalent sensitivity and specificity
would be more acceptable to many patients.
Surface-enhanced laser desorption/ionisation (SELDI) mass
spectrometry (MS) is a technology that can produce proteomic
‘fingerprints’ from biological samples using a relatively high-
throughput platform. The sample is diluted in an appropriate
buffer and applied to ‘proteinchip arrays’ coated with chromato-
graphic surfaces (anion and cation exchange, reverse-phase
and immobilised divalent metal ion surfaces). A proportion of
the peptides/proteins in the sample bind to the chip surface and
the rest of the proteins and any other nonbinding components are
rinsed away. Following addition of an energy absorbing organic
acid the proteins on the surface are ionised into the gas phase
using a laser and analysed by time-of-flight mass spectrometry (i.e.
according to their mass/charge ratio). Multivariate analysis can
then be used to determine whether the intensities of the peaks in
the SELDI spectra of different patient groups possess discrimina-
tory ability. Studies have suggested the possible utility of SELDI
analysis in diagnosing ovarian (Petricoin et al, 2002; Kozak et al,
2003), prostate (Adam et al, 2002; Qu et al, 2002; Banez et al, 2003),
breast (Li et al, 2002), bladder (Vlahou et al, 2001), hepatic (Poon
et al, 2003; Ward et al, 2006) and pancreatic cancer using serum.
Concerns with several aspects of this approach have been raised,
including potential bias in sample collection protocols, accuracy/
resolution of the PBS IIc mass spectrometer employed in SELDI
analysis, alignment of the detected peaks and over fitting of the
data (Ransohoff, 2004). However, the potential benefits of a
sensitive and reliable serum-based diagnostic test for a range of
diseases, including cancer are so great that many efforts are being
made to solve these problems.
More recently, SELDI and other MALDI-based approaches have
been used to detect proteins that are differentially expressed between
patient groups that can then be isolated and identified, often using
MS/MS approaches (Le et al,2 0 0 5 ;M a l i ket al, 2005; Paradis et al,
2005). This information could be useful in the design of more
specific diagnostic tests or inform us about the disease process.
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samples by SELDI and identify proteins responsible for peaks
which characterise the CRC samples and therefore have the
potential to function as biomarkers.
MATERIALS AND METHODS
Patient/sample information
Serum samples were obtained from patients attending the
University Hospital Birmingham rapid-access clinic for primary
care referrals with suspected CRC, or from healthy volunteers.
Ethical approval was obtained for sample collection and all
patients gave informed consent. Blood was collected into standard
hospital blood collection tubes and allowed to clot at 41C for
1–2h, then warmed to room temperature for 30min before
centrifugation (2500g for 10min) and the serum aliquoted
and stored at  801C. Cancers (62 samples) and controls
(31 samples) were collected into identical tubes and processed in
an identical manner.
The noncancer group consisted of 13 male and 18 female
patients vs 36 male and 26 female patients for CRC, aged 62.97
10.3 years for the noncancer vs 67.3712.9 years for CRC. The CRC
group contained 27 patients with localised disease (Dukes’
A/B) and 35 patients with disseminated disease (Dukes’ C/D).
The noncancer group (31 samples) contained patients from the
same rapid-access clinic (27) as the CRC patients (12 diverticular
disease, 15 no abnormality detected) or healthy volunteers (4). The
noncancers were predominantly individuals referred to the rapid-
access clinic because of indicative symptoms that were determined
to not have CRC and the cancers were individuals proven to have
CRC by attending the same clinic. This represents the ‘real-world’
comparison presented to colon practitioners when diagnosing
colon cancer, rather than healthy controls that may not constitute
as relevant a comparison for a diagnostic test.
SELDI analysis
Sera were analysed on Cu
2þ-loaded IMAC30 proteinchip arrays.
The samples (including duplicates) were randomised with respect
to position in the bioprocessor. IMAC proteinchip arrays were
prepared by incubation with 100mM CuSO4 for 5min (50ml per
spot) followed by a water rinse and 3 10min washes with 200ml
binding buffer (500mM NaCl, 100mM NaH2PO4/NaOH, pH 7.0).
All sera were diluted five-fold in 9 M urea, 50mM Tris/HCl, pH 9.0,
2% (wv
 1) CHAPS, followed by a 10-fold dilution in binding
buffer before the addition of 100ml diluted sample per well.
Binding was allowed to proceed for 1h at room temperature with
shaking at 900r.p.m. The proteinchip arrays were then washed
four times using 200ml of binding buffer (10min with shaking)
followed by a water rinse. The proteinchip arrays were allowed to
dry and 1ml of a 50% saturated solution of sinapinic acid in
50% acetonitrile, 0.5% trifluoroacetic acid (matrix solution)
applied to each spot. After air drying, another 1ml of matrix
solution was added and the spots air-dried before analysis in a PBS
IIc SELDI-TOF equipped with an autoloader (Ciphergen, Bio-
systems Inc., Fremont, CA, USA). Spectra were collected over 0–20
and 0–200kDa ranges (600 laser shots) using laser intensity
settings of 165/185 (low range/high range). Spectra were externally
calibrated using neurotensin, cytochrome c, myoglobin, chymo-
trypsinogen and bovine serum albumin (Sigma-Aldrich, Poole,
Dorset, UK) and the intensities normalised using the total ion
current. Spectra with a total ion current of less than 20% of
the average for the experiment were excluded from the analysis.
Peaks were detected automatically using Ciphergen proteinchip
software (valley depth and peak height both set at two times
the noise) and those peaks present in 410% of the spectra
clustered using the Biomarker Wizard tool (manufacturer’s default
settings). Peak intensities for duplicate spectra were combined and
compared between the noncancer and CRC groups using two-
sample t-test and the area under the receiver operator character-
istic (ROC) curve. Peaks found to be statistically significantly
different between the groups were used to develop artificial neural
networks (ANNs).
Sample classification
Artificial neural networks were used to classify serum samples into
cancer and noncancer as described previously (Ward et al, 2006).
The feedforward neural networks consisted of three layers: an
input layer, a hidden layer and an output layer. The number of
input nodes was determined by the number of significant peaks
from which the models were trained. The hidden layer connected
the input and output layers and the number of nodes in this layer
controlled the complexity and performance of the neural networks.
The output layer consisted of a single node whose output was
used to classify sample status, representing cancer or noncancer.
The model had full connection from the input nodes to the hidden
nodes and from the hidden nodes to the output node. All of the
connection weights were randomly initialised in the range ( 1,
þ1). The networks were trained using the back propagation
algorithm and tested using 10-fold cross validation.
Biomarker purification
The initial step in the purification of the 6.44, 6.64, 8.94 and
50.7kDa peaks (based on a method validated by our group
previously; Poon et al, 2003) was to dilute the serum (100ml) three-
fold in 9 M urea, 50mM Tris/HCl, pH 9 and 2% CHAPS buffer, and
apply it to Q Ceramic HyperD F anion exchange beads (Pall, New
York, USA) in spin-cup filters (Pierce, Rockford, Illinois, USA).
The proteins that did not bind were collected by centrifugation.
The beads were then washed sequentially with buffers at pH 7, 5, 4,
and 3, and finally with 50% acetonitrileþ0.5% trifluoroacetic
acid and the eluates collected. The 8.94kDa peak did not bind
to the beads and the only additional purification step was
SDS–PAGE. The 6.64 and 6.44kDa peaks bound to the beads
and eluted predominantly at pH 5. This fraction was applied to a
C-18 reverse-phase column (Vydac, 4.6   300mm) equilibrated in
solvent A (0.1% TFA in water) and proteins eluted using a linear
gradient of 0% solvent B (0.08% TFA in acetonitrile) to 100% B
over 40min at a flow rate of 0.5mlmin
 1. The fractions were
analysed by SELDI and those containing the 6.64 and 6.44kDa
peaks concentrated by vacuum evaporation and then separated by
SDS–PAGE. The 50.7kDa peak eluted at pH 4 and was also
separated using reverse phase HPLC and analysed by SELDI but
this time using the second dimension of a Beckman Coulter PF 2D
protein purification system (see below).
The 79.1kDa protein was purified using a Beckman Coulter PF
2D-automated two-dimensional chromatography system. Pooled
noncancer and pooled CRC sera were run in triplicate on the
system. The sera were diluted in the pH 8.5 ‘start buffer’ and the
protein concentration measured (Pierce BCA protein assay). Total
protein (2.5mg) for each sample was applied separately to the first
dimension (chromatofocusing) at a flow rate of 0.2mlmin
 1,ap H
gradient formed using ‘elution buffer’ (pH 4.0) and fractions
collected every 0.3 pH unit. Fractions from this first dimension
were diluted and applied to Cu
2þ-loaded IMAC proteinchip arrays
and the fractions containing the 79.1kDa peak determined.
The second dimension consists of a monolithic C-18 reverse
phase column (equilibrated in solvent A) used to fractionate
sequentially each of the first dimension fractions. Proteins
were eluted using a linear gradient of solvents A to B over
30min at a flow rate of 0.75mlmin
 1 and fractions collected.
Proteins eluted from the second dimension separation were
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dimension fractions derived from the first dimension fractions
that contained the 79.1kDa peak were again screened by SELDI
and the fractions containing the 79.1kDa peak were separated
by SDS–PAGE.
The individual proteins from the purification schemes given
above were processed for liquid chromatography-tandem mass
spectrometry (LC-MS/MS). Briefly, the band of interest was
excised, washed, reduced using 50mM dithiothreitol, alkylated
with 100mM iodoacetamide and digested overnight with 250ng
modified trypsin (Promega, Madison, Wisconsin, USA). The
LC-MS/MS analysis was performed using an LC Packings Ultimate
HPLC system linked to a ThermoFinnigan LCQ Deca XP Plus
ion-trap mass spectrometer via a nanospray interface fitted
with a metal emitter tip. The peptides were separated using a
180mM ID ThermoFinnigan BioBasic C-18 reverse phase-column
run at 1.25mlmin
 1 that was equilibrated with 95% solvent C (5%
acetonitrile in water/0.1% formic acid) and 5% solvent D (95%
acetonitrile in water/0.1% formic acid) and eluted with a gradient
of 5–37.5% D over 25min. The ion-trap was set to detect positively
charged ions using a spray voltage of 2.5kV and an automated
data-dependent MS/MS analysis performed on the five most
abundant ion species from each MS full scan before another MS
full scan was performed. Peptides were analysed a maximum of
two times and were then placed on an exclusion list for 1min. The
MS/MS spectra were searched against an NCBI nonredundant
human database using TurboSequest as part of the Bioworks 3.1
suite of programmes. All analyses were carried out at least twice
and only proteins with multiple peptides detected, using XCorr
cutoff values of 2.5 for triply, 2.0 for doubly and 1.5 for singly
charged ions, are given.
Western blots were performed on samples after SDS–PAGE
using Immobilon PVDF membrane. The antibodies used were,
anti-C3a antibody from Research Diagnostics Inc., Concorde,
Massachusetts (catalogue number RDI-PRO61018), anti-apolipo-
protein C1 from Chemicon International Inc., Temecula California
(catalogue number MAB 1064), anti-a1-antitrypsin from Abcam,
Cambridgeshire, UK (catalogue number ab9399) and anti-
transferrin from Abcam (ab1223). Where immunodepletions were
performed the antibodies were pre-bound to Protein-G beads
before addition to the serum. The depleted sera were retained
following removal of the beads and associated proteins. The beads
were washed and eluted with 50% acetonitrile/0.5% trifluoacetic
acid. Control incubations using irrelevant antibodies or no
antibody were performed to confirm specificity.
Immunoassays
The C3a ELISA was carried out using a kit from Research
Diagnostics Inc. according to the manufacturer’s instructions.
Carcinoembryonic antigen was measured using a Roche Modular
Immunoassay E170 analyser using the manufacturer’s reagents
and recommended methodology at the Worcestershire Acute
Hospitals Trust.
RESULTS
A SELDI analysis of CRC patient’s sera for the low range (0–
20000m/z) and high range (0–200000m/z) were performed and
two-sample t-tests were carried out to determine which peak
intensities were significantly different in the noncancer vs CRC
groups (see Table 1) using the SELDI spectra from individual
patients. Varying numbers of the most significant peaks were then
used to develop ANNs to discriminate between cancer and
noncancer with 10-fold cross-validation. The ANNs developed
using the seven most significant peaks performed best giving a
sensitivity of 94% and specificity of 96%.
A pooled CRC sample (containing serum from 46 individuals)
and a pooled noncancer sample (26 individuals) were analysed in
quadruplicate on 10 IMAC proteinchip arrays prepared at intervals
over an 11-week period. This experiment was designed to assess
the reproducibility of the analysis and also to confirm proteomic
features characteristic of colon cancer. The average intrachip
coefficient of variation (CV) for the peak intensities in both
samples was 18% and the average CV for both samples across all
10 proteinchip arrays was 25%. In addition, the Euclidean distance
and correlation coefficient (always 40.97) between the peak
heights on each of the 10 proteinchip arrays, relative to the first
proteinchip array, did not show any trends across the experiment.
These data demonstrate that SELDI spectra are reproducible over
extended periods if materials and methods are not changed. The
results in Table 2 show the peaks that are detected as significantly
different between the two pooled samples (here the P-values do
not reflect biological but simply experimental variation). Many of
these peaks are the same (marked with *) as those found to be
significantly different in the analysis of the individual samples
Table 1 Significant proteomic features from individual serum samples
Peak (m/z) P (t-test) AUC Fold change
4790 6.0 10
 6 0.786 0.67
50700 7.1 10
 6 0.798 1.71
8940 0.00020 0.739 1.48
6440 0.00026 0.705 0.68
6640 0.00057 0.690 0.72
123000 0.00065 0.712 0.75
4290 0.00077 0.701 0.67
8150 0.0014 0.682 1.31
76000 0.0024 0.678 1.37
8760 0.0035 0.721 0.62
4480 0.0039 0.685 1.55
79100 0.0043 0.676 1.21
39900 0.0052 0.738 1.38
AUC, area under the ROC curve. SELDI peaks significantly different in the sera of
CRC patients. Serum samples from control and cancer patients were analysed in
duplicate using Cu
2+-loaded IMAC proteinchip arrays. The peak intensities between
controls and cancer were compared and the fold change (cancer relative to controls)
and significance are given. ROC curves for the significant peaks (P40.05) were
constructed and the area under the curve for each peak is shown.
Table 2 Significant peaks from the analysis of pooled samples
Peak (m/z) P (t-test) Fold change
8150* 1.4 10
 12 1.21
39900* 8.9 10
 12 1.56
79100* 1.0 10
 9 1.32
50700* 3.9 10
 9 1.31
11530 1.0 10
 7 3.01
9000 4.3 10
 7 1.22
11690 1.3 10
 6 2.20
2285 6.9 10
 6 0.72
4290* 1.8 10
 5 0.75
5920 2.3 10
 5 0.87
8940* 0.00028 1.20
7940 0.00039 1.09
4480* 0.00050 1.19
6640* 0.00076 0.79
3970 0.0012 1.20
6440* 0.0016 0.78
Pooled control and cancer samples were analysed 40 times using Cu
2+-loaded IMAC
proteinchip array. The peak intensities for the samples were compared and the
significantly different peaks (P40.05) are listed along with the P-value and fold
change. Peaks marked with * are those that are also significantly different in the SELDI
profiles of the individual samples given in Table 1.
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experiments were considered as suitable candidates for purifica-
tion and identification.
The initial strategy to isolate the peaks of interest was based on
the serum fractionation protocol used by Poon et al (2003). The
sera were diluted in a buffer designed to disrupt protein/protein
interactions (9 M urea and 2% CHAPS, pH 9). Under these
conditions, proteins with a pI below pH 9 bind to anion exchange
resin and those with a pI above pH 9 do not. The bound proteins
can then be eluted by washing the resin sequentially with buffers of
decreasing pH. The nonbinding sample and the various eluates
were analysed using Cu
2þ-loaded IMAC30 proteinchip arrays and
the fractions containing the peaks of interest determined.
The 8.94kDa peak did not bind to the anion exchange resin at
pH 9, and when the nonbound material was separated by SDS–
PAGE, a differentially expressed band of approximately the
expected mobility was seen (data not shown). In-gel digestion
and LC-MS/MS analysis of this band detected four tryptic peptides
(Table 3) derived from complement C3, a protein with a predicted
mass of 185kDa that is cleaved to produce complement C3a
with a mass of 9095Da. This protein has its C-terminal arginine
residue removed to produce complement C3a des-arg with a mass
of 8938Da corresponding closely to the mass of the differentially
detected peak in the SELDI analysis. All of the complement C3
tryptic peptides detected were from within the complement C3a
des-arg sequence and represent 27% of the C3a des-arg.
Complement C3a des-arg has a predicted pI of 9.3 in agreement
with the observation that this molecule did not bind to the anion
exchange resin at pH 9. The identity of the SELDI peak at 8.94kDa
was verified using an anti-complement C3a antibody to deplete
complement C3a from serum. The SELDI peak at 8.94kDa was
specifically removed from the serum by the antibody treatment
and was subsequently recovered following elution from the
antibody (Figure 1) confirming the identity of the 8.94kDa peak
as complement C3a des-arg.
In order to relate the SELDI peak intensities with complement
C3a des-arg abundance, a complement C3a des-arg ELISA was
performed. The result in Figure 2 shows a correlation between the
SELDI peak intensity and the ELISA determined C3a abundance.
The 6.44 and 6.64kDa peaks coeluted from the ceramic HyperD
F anion exchange resin in the pH 7–4 fractions. The sample
containing the most intense peaks (pH 5 elution) was separated
using RP–HPLC and the eluted fractions screened by SELDI. The
fractions containing the 6.44 and 6.64kDa peaks were separated
using SDS–PAGE and a band with the correct mobility excised,
digested and analysed using LC-MS/MS. Six peptides covering 56%
of the sequence of apolipoprotein C1 were detected (Table 3).
Apolipoprotein C1 has a predicted sequence mass of 6631Da
and an additional truncated form with threonine and proline
removed from the N-terminus with a mass of 6433Da has been
reported (Bondarenko et al, 1999). Immunodepletion of serum
using an anti-apolipoprotein C1 antibody removed both the 6.44
and 6.64kDa peaks, which were recovered following elution from
the antibody (Figure 3A). Western blot analysis of serum samples
(Figure 3B) did not detect any differences in apolipoprotein C1
concentration.
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Figure 1 Immunodepletion of complement C3a des-arg. Serum was
incubated with an anti-complement C3a des-arg mouse monoclonal
antibody bound to protein G sepharose. The protein G sepharose was
collected by centrifugation and the non-bound proteins (depleted serum)
retained. The beads were washed and the bound proteins eluted. The
starting serum (upper panel), non-bound proteins (middle panel) and
eluted proteins (lower panel) were analysed using Cu
2þ-loaded IMAC
proteinchip arrays.
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Figure 2 Comparison of the SELDI peak intensity at 8940m/z and the
complement C3a levels in serum. The complement C3a des-arg level was
measured using an ELISA kit from Research Diagnostics Inc. using the
manufacturer’s instructions. The results shown are the concentration of
C3a (mgml
 1) plotted against SELDI peak intensity in the same sample.
Table 3 Tryptic peptides used to identify the 6.44/6.64 and 8.94kDa
biomarkers
Peptide MH+ ID
FISLGEACK 1025.2 Complement C3a residues 42–50
FISLGEACKK 1153.4 Complement C3a residues 42–51
VFLDCCNYITELR 1703.9 Complement C3a residues 52–64
KVFLDCCNYITELR 1832.1 Complement C3a residues 51–64
TPDVSSALDK 1033.1 Apolipoprotein C1 residues 1–10
EFGNTLEDK 1053.1 Apolipoprotein C1 residues 13–21
EWFSETFQK 1202.3 Apolipoprotein C1 residues 40–48
TPDVSSALDKLK 1274.5 Apolipoprotein C1 residues 1–12
LKEFGNTLEDK 1294.4 Apolipoprotein C1 residues 11–21
MREWFESTFQK 1489.7 Apolipoprotein C1 residues 38–48
Partially purified proteins were separated using SDS-PAGE and the relevant gel slice
excised, reduced, alkylated and trypsinised. The peptides were collected and
subjected to LC-MS/MS analysis followed by a database search to identify the
peptides. The upper panel shows the peptides derived from complement C3a and
the lower panel the peptides from apolipoprotein C1.
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F anion exchange resin at pH 4 and was further purified by
RP-HPLC and the relevant fractions separated by SDS–PAGE. A
band migrating with an apparent MW of 50.7kDa was excised and
trypsinised, and the peptides harvested. LC-MS/MS analysis
detected 27 unique peptides from a1-antitrypsin (50% sequence
coverage) and seven unique peptides from a1-antichymotrypsin
(20% sequence coverage). Both of these proteins are glycosylated,
have similar molecular masses and isoelectric points and their
co-purification has been reported previously (Koomen et al, 2005).
It seemed likely that a1-antitrypsin is the major contributor to
the 50.7kDa biomarker peak and this was confirmed by Western
blot and immunodepletion. Furthermore, the SELDI peak intensity
and Western blot staining (Figure 4) correlate, indicating that the
concentration of a1-antitrypsin is higher in the serum of CRC
patients in this study, as detected by SELDI peak height.
The 79.1kDa biomarker was purified by 2D liquid chromato-
graphy (Beckman-Coulter PF 2D system) resulting in an essentially
pure 79.1kDa protein that binds to the IMAC proteinchip array
(Figure 5B). This protein was identified as transferrin (44 unique
peptides giving 57% sequence coverage). Absorbance at 214nm
of the transferrin revealed a modest increase in concentration
in the pooled CRC sample relative to the pooled normal sample in
agreement with the SELDI analysis, and Figure 5A shows
the SELDI analysis of the immunodepletion/elution. The anti-
transferrin antibody decreased the intensity of the 79.1kDa
peak, which was specifically detected in the eluted material.
The SELDI spectra obtained during the purification of the
transferrin showed a co-purifying peak of 39900m/z that is
not seen in the stained gel (Figure 5B and C), which corresponds
to the m/z of a differentially expressed peak in the SELDI
IMAC chip analysis of individual and pooled samples (Tables 1
and 2). When the transferrin immunodepletion was performed, the
SELDI peak at 39.9kDa was also decreased and recovered in
the eluted material (not shown) and commercially available
purified transferrin displayed two peaks of approximately
79.1 and 39.9kDa (not shown). It is possible therefore that the
39.9kDa peak is the doubly charged transferrin ion, but the
mass of the ion does not correspond accurately to the predicted
m/z value, which may be due to the relatively low mass accuracy of
the PBS II analyser.
Sample classification using only the six SELDI peaks
corresponding to apolipoprotein C1, complement
C3a des-arg, a1-antitrypsin and transferrin
Using unidentified peaks in SELDI spectra to classify patients
is essentially a ‘black box’ approach. Having identified six of
the peaks (the 6.44, 6.64, 8.94, 50.7, 79.1 and the potentially
doubly charged version of the 79.1kDa protein at 39.9kDa),
an ANN was developed using only these peaks. This ANN was able
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Figure 3 Immunodepletion of apolipoprotein C1 and a comparison of
the intensity of the peak at 6640m/z with Western blot analysis of
apolipoprotein C1. (A) Serum was depleted using an anti-apolipoprotein
C1 mouse monoclonal antibody using the same protocol given for the
immunodepletion of complement C3a given in Figure 1. (B) A Western
blot using an anti-apolipoprotein C1 antibody. The whole length and
truncated forms of apolipoprotein C1 differ in mass by 198Da and are not
resolved by the SDS–PAGE so only a single band is observed. The samples
were selected on the basis of a high or low SELDI peak height, as shown in
(C). The SELDI peak intensity at 6640m/z using Cu
2þ-loaded IMAC
proteinchip arrays for the same samples for the Western blot is shown. The
6440m/z peak displayed a similar pattern of intensities as the 6640m/z
peak (results not shown).
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Figure 4 Immunodepletion of a1-antitrypsin and a comparison of the
intensity of the peak at 50700m/z with Western blot analysis of a1-
antitrypsin. (A) An immunodepletion of a1-antitrypsin using a mouse
monoclonal antibody was performed using the same strategy given in
Figure 1 for complement C3a. (B) Western blot analysis of eight samples
(C) Corresponding SELDI intensity for the 50700m/z peak. The samples
used were selected on the basis of the 50700m/z peak intensity to asses
the correlation between Western blot analysis and SELDI peak hight.
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(10-fold cross validation).
Comparison and combination of ANNs with CEA
Carcinoembryonic antigen was measured in all of the samples, and
using the manufacture’s recommended cutoff level of 4ngml
 1,
the sensitivity and specificity obtained was 53 and 93%,
respectively. Furthermore, inclusion of the CEA data in an ANN
with the SELDI data for the six SELDI peaks identified here did not
improve the ANN for the SELDI peaks alone.
DISCUSSION
The results presented in this paper demonstrate that SELDI
analysis of CRC serum, compared to noncancer detects an altered
intensity in a number of characteristic peaks which, when analysed
by ANNs, have sensitivities and specificities in excess of 90%. This
work identified some of these peaks as transferrin, a1-antitrypsin,
complement C3a des-arg and apolipoprotein C1. A similar use
of SELDI by Chen et al (2004), Guang et al (2004) and Yu et al
(2004) suggested that SELDI profiling could be more sensitive
than CEA analysis in diagnosing CRC. The data in this paper
support this, but, additionally, identifies potential biomarkers,
which require validation with large numbers of patients and if
successful could point to the development of more widely
applicable immunoassays.
In this study, we screened for biomarkers in two distinct
ways: (1) multiple measurements of two pooled samples contain-
ing serum from many noncancer controls or CRC patients and (2)
duplicate measurements of serum from many noncancer indivi-
duals or patients with CRC. The first approach gave a thorough
investigation of how reproducible SELDI peak heights were during
this study: we find the intrachip CV to be within the manu-
facturer’s specification and an overall CV of 25%. Using the second
approach, we collected duplicate SELDI spectra for each serum
sample from 31 noncancer controls and 62 CRC patients. Having
separate data on all the individuals in the study allowed us to
assess diagnostic utility (area under the ROC curve, see Table 1)
and to develop algorithms for patient classification. It can be seen
that regardless of which of these two methods is employed,
the majority of the peaks identified as significantly different in the
CRC patients were the same (Tables 1 and 2).
The four proteins that we have identified as underlying six
of the SELDI peaks with diagnostic potential are all classical
serum proteins; however, this need not exclude their use as cancer
biomarkers (Poon et al, 2001). The pair of peaks detected at 6440
and 6640m/z were shown to be full-length apolipoprotein C1 and a
truncated version that has been described previously (Bondarenko
et al, 1999). Both of the peaks at 6440 and 6640m/z were
detected at decreased intensities in the CRC samples when the
IMAC proteinchip array was employed (Tables 1 and 2). However,
when the H50, Q10 and CM10 proteinchip arrays were used no
differences in intensities were detected (results not shown).
Furthermore, a Western blot for apolipoprotein C1 did not detect
any difference between samples selected (Figure 3) on the basis of
the intensity of the 6440 and 6640m/z peaks determined using the
IMAC proteinchip array. The reason for this is not clear but may
be related to competition for binding at the retentate chromato-
graphy step and/or suppression of ionisation during the ionisa-
tion/desorption step. Presumably, the binding of these proteins to
the IMAC proteinchip array and/or the ionisation/desorption step
is influenced by underlying biochemical changes in one of the
sample groups that do not interfere with the other proteinchip
array types. This need not exclude the use of these discriminatory
peaks in the development of ANNs to diagnose cancer if the
observed differences are suitable for the purpose.
The identification of the peak at 8940m/z, as complement C3a
des-arg using MS/MS analysis was confirmed using an immuno-
depletion approach (Figure 1). Chen et al (2004) also detected an
elevation of a peak at 8930m/z in samples from colon cancer
patients that may be the same protein. A peak of similar mass was
identified as apolipoprotein A-II in prostate cancer samples (Malik
et al, 2005) and as a fragment of vitronectin in hepatocellular
carcinoma samples (Paradis et al, 2005), underlining the need to
validate identifications using independent assays. The increased
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Figure 5 Immunodepletion and purification of transferrin. (A)A n
immunodepletion of transferrin employing an identical protocol to that in
Figure 1. The peak of 79100m/z was purified by automated 2D HPLC and
the fractions monitored using SELDI. A Coomassie-stained SDS–PAGE gel
shows a clear single band at approximately 80kDa (B). (C) SELDI
spectrum of this purified protein with a peak at the predicted size of
79100m/z in addition to an another at 39900m/z.
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suggested an increased level of complement activation indicative
of inflammation. Complement C3a is highly biologically active,
binding to mast cells and basophils and triggering release of
their vasoactive contents (the des-arg form represents a stable
inactivated form of complement C3a). The elevated level of
complement C3a des-arg in the serum of CRC patients may reflect
an immune response to the tumour, or possibly in vitro
complement activation (Mollnes et al, 1988). This is unlikely to
be a problem in this study as all samples were handled in an
identical manner and therefore any differences in in vitro
complement activation should reflect the state of the complement
system in the samples. The complement C3a ELISA assay shows
that the SELDI intensity reflects the serum concentration but the
two measurements were not absolutely comparable. The antibody
used in the ELISA recognises the C-terminus of the peptide and
hence will react with any complement C3 cleaved at this site,
whereas the SELDI peak will only report on complement C3a des-
arg (if, e.g., N-terminally truncated forms existed, then these would
not contribute to the peak at 8940m/z).
The levels of a1-antitrypsin determined by SELDI and Western
blot (Figure 4) correlate well, indicating that a1-antitrypsin is
elevated in the CRC patients in this study. Koomen et al (2005)
recently reported that a broad SELDI peak around 51.5kDa was
differentially detected in serum from pancreatic cancer patients
compared to controls. This peak was found to contain a1-
antitrypsin, a1-antichymotrypsin (as observed here) and hapto-
globin. Measurement of the haptoglobin levels did not show a
difference between the control and cancer patients, but as multiple
proteins were found in the peak it is quite possible that the
difference was owing to an altered level of one or both of the other
proteins, as we show here for a1-antitrypsin. Like the elevation in
complement C3a des-arg, this suggests that an inflammatory
response to the tumour is occurring. As such, it is unlikely that
either protein would show high specificity for CRC (Koomen et al,
2005); however, they may be candidates for multiplexed immuno-
assays combining sensitive and specific biomarkers.
Acute phase proteins are usually defined as proteins that
change concentration by 25% or more in response to a range of
inflammatory disorders. The majority of proteins increase in
concentration but transferrin is one that decreases. Here, we
detect an increase in a peak of approximately 79.1kDa in the
serum of CRC patients compared to controls that was identified
as transferrin (Figure 5). The primary function of transferrin is to
transport iron around the body. Elevated body iron stores
have been proposed to correlate with an increased risk of
colon cancer and an increased proportion of transferrin loaded
with iron has been linked with an increased cancer incidence,
particularly in individuals who have a high intake of iron
(Weinberg, 1994; Nelson, 2001; Mainous et al, 2005). It is not
clear why the transferrin concentration is increased in the serum of
colon cancer patients as the predicted response to inflammation is
a decrease for this protein. Clearly, the cancer process is more
complex than inflammation alone, and as iron appears to play a
role(s) in cancer biology, it is possible that the increase in
transferrin concentration observed in the serum of CRC patients is
not an acute phase response.
In conclusion, proteomic profiling of serum from CRC patients
and noncancer individuals, combined with the use of ANNs, can
diagnose CRC with 94% sensitivity and 96% specificity in our
cohort of patients. We have identified four proteins underlying
six of the SELDI peaks that are significantly different between
the noncancer controls and CRC patients. The proteins identified
are common serum proteins and changes in their concentrations
most likely reflect epiphenomena rather than secretion by cancer
cells. Nonetheless, ANNs trained with just the SELDI peaks from
these proteins are remarkably good at discriminating CRC,
outperforming CEA.
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